Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

G3 Announces Completion of Enrollment in GLOBAL Study with 7,500 Patients

Published: Friday, May 30, 2014
Last Updated: Friday, May 30, 2014
Bookmark and Share
Single largest prospective pan-omic study to identify key biomarkers and central therapeutic targets for cardiovascular diseases has completed enrollment.

Global Genomics Group (G3) has announced that it has completed the enrollment of patients in its international, prospective GLOBAL (Genetic LOci and Burden of Atherosclerotic Lesions) study, months ahead of schedule.

GLOBAL is the first pan-omic study designed to identify disease-related pathways, new drug targets and biomarkers for cardiovascular diseases such as atherosclerosis.

"The early completion of the GLOBAL study is a significant milestone for G3 and confirms the strong support and interest from the medical community," said Tonya Mallory, chief executive officer, president and co-founder of Health Diagnostic Laboratory, a strategic partner of G3.

Mallory continued, "G3 is in the process of analyzing the initial data and could have pilot data results as early as the first half of 2015. The study will analyze 22 trillion data points from 7,500 patients and will enable us to gain an in-depth understanding of the biological basis behind the complex processes responsible for atherosclerosis, leading to the identification of new biomarkers for early detection and new targets for the development of novel and effective drugs. As of today, only 20 drug candidates are being developed for atherosclerosis and coronary artery disease, the leading cause of death worldwide."

John Lesser, M.D., one of the principal investigators for the GLOBAL study and former president of the Society of Cardiovascular Computed Tomography, said, "Early disease detection and intervention, as well as effective therapeutic options, remain significant unmet medical needs in cardiovascular disease. It is quite remarkable to see such a large scale, comprehensive study executed so quickly. I am thrilled to be a part of this work, and I am looking forward to the potential of using the clinical diagnostic tests that result."

The GLOBAL study completed the enrollment of 7,500 patients at 48 clinical sites in North America, Europe, and Australia.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!